Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators
Table 1
Comparison of the distribution of the clinical characteristics at the time of initial treatment and at PSA failure for the 53 men in the study cohort stratified by survival status at time of last followup.
Characteristic
Alive,
Dead,
Age at PSA failure—median (IQR), yrs
75.7
77.3
0.10
PSA
(69.4–78.6)
(75.0–80.8)
Doubling time—median (IQR), mo
32.9 (15.0–43.0)
20.3 (10.5–42.6)
0.55
Interval to failure—median (IQR), mo
57.4 (35.0–99.0)
47.2 (38.3–57.9)
0.44
Last PSA level—median (IQR), ng/mL
4.7 (2.9–10.0)
2.4 (1.7–6.9)
0.16
Primary treatment— (%)
Radiation
19 (66)
16 (67)
1.0*
Radiation + ADT
10 (34)
8 (33)
Gleason— (%)
≤6
11 (38)
2 (8)
0.02*
7
16 (55)
16 (67)
8–10
2 (7)
6 (25)
T category— (%)
T1
13 (45)
10 (42)
1.0*
T2
16 (55)
14 (58)
Comorbidity— (%)
None or minimal
27 (93)
14 (58)
0.004*
Moderate or severe
2 (7)
10 (42)
PSA: prostate specific antigen; IQR: interquartile range; ADT: androgen deprivation therapy.
*Fisher exact test value.
